151 related articles for article (PubMed ID: 35146837)
21. Catheter-associated candiduria: Risk factors, medical interventions, and antifungal susceptibility.
Padawer D; Pastukh N; Nitzan O; Labay K; Aharon I; Brodsky D; Glyatman T; Peretz A
Am J Infect Control; 2015 Jul; 43(7):e19-22. PubMed ID: 25920705
[TBL] [Abstract][Full Text] [Related]
22. Catheter-associated urinary tract infections in adult intensive care units at a selected tertiary hospital, Addis Ababa, Ethiopia.
Bizuayehu H; Bitew A; Abdeta A; Ebrahim S
PLoS One; 2022; 17(3):e0265102. PubMed ID: 35316286
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Micafungin for treating
Parramon-Teixido CJ; Garcia Esquerda C; Frick MA; Tripodi C; Gomez-Ganda L; Ruiz-Campillo CW; Cabañas-Poy MJ
Front Pediatr; 2024; 12():1397456. PubMed ID: 38827222
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study.
Zheng X; Huang X; Luo J; Li J; Li W; Liu Q; Niu T; Wang X; Zhou J; Zhang X; Hu J; Liu K
Adv Ther; 2018 Sep; 35(9):1400-1410. PubMed ID: 30105657
[TBL] [Abstract][Full Text] [Related]
25. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
Scott LJ
Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
[TBL] [Abstract][Full Text] [Related]
26. Probiotic use and prevalence of candidemia and candiduria in a PICU.
Kumar S; Singhi S; Chakrabarti A; Bansal A; Jayashree M
Pediatr Crit Care Med; 2013 Nov; 14(9):e409-15. PubMed ID: 23965638
[TBL] [Abstract][Full Text] [Related]
27. Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age.
Abdel-Haq N; Smith SM; Asmar BI
Expert Rev Anti Infect Ther; 2022 Apr; 20(4):493-505. PubMed ID: 34882043
[TBL] [Abstract][Full Text] [Related]
28. Rifaximin use favoured micafungin-resistant Candida spp. infections in recipients of allogeneic hematopoietic cell transplantation.
Marzuttini F; Mancusi A; Bonato S; Griselli M; Tricarico S; Casarola G; Paradiso M; Ruggeri L; Terenzi A; Merluzzi M; Prigitano A; Tortorano AM; Pitzurra L; Falini B; Carotti A; Velardi A; Pierini A
Ann Hematol; 2021 Sep; 100(9):2375-2380. PubMed ID: 34180023
[TBL] [Abstract][Full Text] [Related]
29. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment with caspofungin of candiduria in a child with Wilms tumor; review of literature.
Rezai MS; Vaezi A; Fakhim H; Soleimani A; Mohammad Jafari H; Mohseni S; Badali H
J Mycol Med; 2017 Jun; 27(2):261-265. PubMed ID: 28188050
[TBL] [Abstract][Full Text] [Related]
32. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
Scott LJ
Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
[TBL] [Abstract][Full Text] [Related]
33. [Epidemiological features of Candida infections detected in intensive care units and risk factors affecting mortality].
Acar A; Oncül O; Küçükardali Y; Ozyurt M; Haznedaroğlu T; Cavuşlu S
Mikrobiyol Bul; 2008 Jul; 42(3):451-61. PubMed ID: 18822889
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit.
Phillips JR; Karlowicz MG
Pediatr Infect Dis J; 1997 Feb; 16(2):190-4. PubMed ID: 9041599
[TBL] [Abstract][Full Text] [Related]
35. [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I; Angel Sanz M
Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
[TBL] [Abstract][Full Text] [Related]
36. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
37. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
38. [Micafungin for the treatment of neonatal invasive candidiasis].
Infante-López ME; Rojo-Conejo P
Rev Iberoam Micol; 2009 Mar; 26(1):56-61. PubMed ID: 19463278
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
